ARIAD, NCRI collaborate on Phase III leukemia study
February 2013

CAMBRIDGE, Mass.—An agreement was struck in early January between ARIAD Pharmaceuticals Inc. and Newcastle University, United Kingdom, on behalf of the U.K. National Cancer Research Institute CML Working Group. The organizations will collaborate on a multicenter, randomized Phase III trial to determine the impact of switching chronic myeloid leukemia patients being treated with a first-line tyrosine kinase inhibitor to ponatinib in cases of suboptimal response or treatment failure. The study's primary endpoint will be the proportion of patients who achieve major molecular response (MMR) at three years on their first line of therapy, with secondary endpoints including proportion of patients who achieve therapy cessation three years after achieving stable MMR, therapy cost, safety, tolerability, overall survival, progression- and event-free survival and treatment failure at five years.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.